Deals & Cases

Walder Wyss advises Fresenius Kabi on the acquisition of Merck's biosimilars business

28 April 2017 – Walder Wyss advises, together with Clifford Chance, Düsseldorf, Fresenius Kabi on the acquisition of Merck’s Biosimilar Business and on the intergration of the respective premises in Aubonne and Vevey. Biosimilars are a biological generic preparations of drugs and are expected to be a strongly growing pharmaceuticals market. The purchase price of up to 670 billion Euro consist of a cash compensation of 170 billion Euro payable upon closing and of product related earn out amounts of up to 500 billion Euro. The transaction is subject to the competition authority’s approval and should be completed in summer 2017.

The Walder Wyss team is led by partner Markus Vischer (Corporate M&A) and includes Thomas Meister (partner, Tax), Markus R. Frick (partner, IP Competition), Jan Ole Luuk (counsel, VAT), Janine Corti (counsel, Tax), Christoph Stutz (associate, Emplyoment/Social Security) and Vera Krüttli (associate, Corporate M&A).